Business
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer
About this update from Whitehawk Therapeutics, Inc.
[{"type":"text","content":"Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population\nPRECISION1 tumor-agnostic trial testing nab-sirolimus for patients with TSC 1/2 mutations on track for interim analysis on 40 patients before the end of 2023\nEvaluation of nab-sirolimus in preclinical combination with PI3K and AKT inhibitors indicate enhanced antitumor effects in PIK3CA-mutated breast cancer \nLOS ANGELES, Oct. 12, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced details of four poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston, MA. \nAbstracts and poster presentation details are below:\nTitle: \"Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient population using the Foundation Medicine genomic database\" Poster Number: C019Session Title: Poster Session CDate/Time: Saturday, October 14, 2023, 12:30 pm-4:00 pm EDTAuthors: David J. Kwiatkowski, MD, PhD; Norma A. Palma, PhD; Willis H. Navarro, MD; Gopa Iyer, MD\nAbstract highlights:\nTo appreciate the potential for TSC1 and TSC2 as therapeutic biomarkers, TSC1 and TSC2 mutational data from an RW genomic database were analyzed.Next-generation sequencing data from Foundation Medicine's genomic database of patients primarily with advanced cancer were analyzed using the FoundationInsights™ web-based platform.In a large RW database of patients with advanced cancer, inactivating TSC1 and TSC2 variants occurred in 1.9% of patients. These occurred across common tumor types at rates as high as 8.6% (urinary bladder tumors).These observations suggest cancers with TSC1 and/or TSC2 alterations may be candidates for targeted therapy.Title: \"Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer\" Poster Number: B003Session Title: Poster Session BDate/Time: Friday, October 13, 2023, 12:30 pm-4:00 pm EDTAuthors: David J. Kwiatkowsk...